Novartis US Foundation establishes USD $5 million US COVID-19 Community Response Fund
In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic. Click here to read the April 03, 2020 press release.
Grant requests must fit within the following criteria:
Applicants must be verified 501(c)(3) organizations.
Priority will be given to efforts focused on geographies where Novartis has a physical presence and where there is an acute need, including, but not limited to, NJ, MA, CA, IL, NC, and NY.
Programs must support one or more of the three stated objectives:
Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers
Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information
Creating or enhancing new community health programs specific to the pandemic response
Grant request amounts should be in the range of $100,000 and $250,000.
The following types of requests are not eligible:
R&D efforts related to COVID-19
All programs must adhere to applicable Novartis guidelines and local laws.
As part of our commitment to patients and the healthcare community, Novartis is taking a number of important steps in these areas:
Grants: Through April 30, we are accepting grant requests for COVID-19 Professional Medical Education and have reduced processing timelines to meet the time-critical need of the current situation. This effort is on top of the grants applications we are continuing to accept for our established therapeutic areas.
Education: We are working with US and Global Medical Experts to make up-to-date information available to healthcare professionals. Over the next few weeks, an educational series of videos and podcasts will be developed by Novartis to share medical expert knowledge on COVID-19 specific topics. See below.
Novartis Pharmaceuticals Medical COVID-19 Program Introduction
Episode 01: General Overview of COVID-19
Our patient and healthcare professional call centers are equipped to manage an increased volume and are at the ready to address questions about our products in the COVID-19 context. Additionally, our field-based associates are equipped to serve HCPs 100% virtually through:
Fulfillment of product sample requests.
Remote information sharing and in some cases, screen sharing capability, to equip physicians with educational tools and information to support patient care.
Peer-to-peer interactions, which enhance experience and knowledge sharing, while creating and strengthening communities of support.
Ensuring Patient Access During COVID-19
During these uncertain and uniquely challenging times, we know that many people are facing hardships resulting from job loss, illness, or strained access to healthcare services. We stand ready to support those in need by providing relief through our many patient support programs.
We believe that our commitment to ensuring access to our medicines has never been more important. In the last five years, approximately 299,000 patients received free medication valued at over USD 7.9 billion through the Novartis Patient Assistance Foundation Inc. And, in 2019, approximately 520,500 patients received copay assistance.
Now, we are building on this legacy by enhancing our offerings to help those experiencing difficulties resulting from the COVID-19 crisis. This includes simpler access to free medicines for eligible patients and expanded programs to improve affordability and patient support. We will continue to monitor and expand our services where possible to ensure patients have access to the support they need during this challenging time.
Patient Assistance NOW
Through our Patient Assistance NOW website, we help all patients find programs that may provide savings or resources, as well as access to their Novartis prescriptions medications. The website is easy to navigate; patients just answer a few questions to find out what programs they qualify for.
The Novartis Patient Assistance Foundation, Inc. (NPAF)
Patients experiencing financial hardship and have limited or no prescription coverage may be eligible to receive Novartis medications for free. This includes those who may experiencing a sudden job loss or loss of insurance due to COVID-19. We have simplified the application process to ensure patients get the medicines they need easily and quickly. Click here or call 1 800 277 2254 for more information NPAF.
Patient Support Programs for Each Novartis Medication
In light of COVID-19, Novartis is implementing flexible therapeutic access and support, wherever possible, for some of our most widely-used medicines through our patient support programs for each of our medications. For example, this may include free temporary supplies of certain medications to avoid treatment gaps, expanded in-home onboarding and administration support, extended fill co-pay card support, and where available, extended refills for free-drug programs. Contact 1-800-NOW-NOVA or visit the specific Novartis medication website for information on how to enroll.
We have also ramped up our services to help answer patients’ general and therapy-specific COVID-19 questions – and leveraging our Patient & Specialty Services team to perform virtual outreaches to patients, as appropriate, to lend support.
We are here to answer patient questions and can be reached at 1-888-NOW-NOVA (1 888 669 6682) Monday - Friday, 8:30 AM - 5:00 PM ET. In case of Medical Emergency, please contact your physician immediately.
Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services